Who are ION363's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Del-desiran (AOC 1001), EZN-2279, Qalsody, Amondys 45, Vyondys 53, Exondys 51.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ion363.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

ION363 — Competitive Intelligence Brief

ION363 (ION363) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antisense oligonucleotide. Area: Cardiovascular.

phase 3 Antisense oligonucleotide APOC3 mRNA Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

ION363 (ION363) — Ionis Pharmaceuticals, Inc.. ION363 is an antisense oligonucleotide that reduces production of apolipoprotein C-III (apoC-III), a protein that impairs triglyceride clearance and increases cardiovascular risk.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ION363 TARGET	ION363	Ionis Pharmaceuticals, Inc.	phase 3	Antisense oligonucleotide	APOC3 mRNA
Del-desiran (AOC 1001)	Del-desiran (AOC 1001)	Avidity Biosciences, Inc.	phase 3	Antisense oligonucleotide	APOC3 mRNA
EZN-2279	EZN-2279	Leadiant Biosciences, Inc.	phase 3	Antisense oligonucleotide	APOC3 mRNA
Qalsody	TOFERSEN	Biogen Ma	marketed	Antisense Oligonucleotide [EPC]	Superoxide dismutase 1 (SOD1) mRNA	2023-01-01
Amondys 45	CASIMERSEN	Sarepta	marketed	Antisense Oligonucleotide [EPC]	exon 53 of dystrophin pre-mRNA	2021-01-01
Vyondys 53	GOLODIRSEN	Sarepta	marketed	Antisense Oligonucleotide [EPC]	exon 53 of dystrophin pre-mRNA	2019-01-01
Exondys 51	ETEPLIRSEN	Sarepta	marketed	Antisense Oligonucleotide [EPC]	exon 51 of dystrophin pre-mRNA	2016-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antisense oligonucleotide class)

Ionis Pharmaceuticals, Inc. · 3 drugs in this class
Sarepta Therapeutics, Inc. · 2 drugs in this class
Isarna Therapeutics GmbH · 1 drug in this class
Leadiant Biosciences, Inc. · 1 drug in this class
NYU Langone Health · 1 drug in this class
Avidity Biosciences, Inc. · 1 drug in this class
Ultragenyx Pharmaceutical Inc · 1 drug in this class
European Organisation for Research and Treatment of Cancer - EORTC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ION363 — Competitive Intelligence Brief. https://druglandscape.com/ci/ion363. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab